Drug Profile


Alternative Names: 33525; 33525 cream; Lulicon; Lulicon Cream 1%; Lulicon Solution 1%; Lulifin; Luzu; NND-502

Latest Information Update: 19 Sep 2015

Price : $50

At a glance

  • Originator Nihon Nohyaku
  • Developer POLA; Sun Pharmaceutical Industries; Tinea Pharmaceuticals Inc; Valeant Pharmaceuticals International
  • Class Antifungals; Imidazoles; Skin disorder therapies; Small molecules
  • Mechanism of Action Sterol demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Mycoses; Tinea corporis; Tinea cruris; Tinea pedis
  • Phase II/III Onychomycosis

Most Recent Events

  • 16 Sep 2015 Antimicrobial data from a in vitro potency study in Onychomycosis released by TOPICA Pharmaceuticals
  • 18 Jun 2015 Luliconazole is still in phase II/III development for Onychomycosis in USA
  • 25 Mar 2015 Ranbaxy Laboratories has been acquired by Sun Pharmaceutical Industries
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top